Glioma Surgery

  • Joanna Ashby
  • Colin WattsEmail author


Neurosurgical intervention is essential for the safe and effective management of adult gliomas. Increasing evidence suggesting that for both low- and high-grade gliomas, maximal cytoreduction is associated with an increased overall survival. Beyond conventional neurosurgical principles, there are a variety of techniques that have been refined over the last decade to maximise the efficiency of the neurosurgeon and post-operative management. Functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) are two non-invasive techniques used to localise eloquent motor and language anatomy and higher cognitive pathways to inform decision-making and preoperative surgical planning. Novel intraoperative techniques include neuronavigation, cortical and subcortical mapping, high-frequency ultrasonography, Raman spectroscopy, fluorescence-guided surgery and locally delivered therapies such as carmustine. These therapies are valuable tools which act to reduce post-operative neurological deficits therefore reducing the overall tumour burden on the patient by improving quality of life. Operating on elderly patients with gliomas, as well as those with recurrent disease, is still controversial but is becoming more common due to advances in adjunct technologies. In summary this collection of management strategies has aided the neurosurgeon in achieving optimal surgical cytoreduction in the management of adult glioma.


Surgery Glioma High-grade glioma (HGG) Neuronavigation Direct cortical stimulation Intraoperative magnetic resonance imaging (iMRI) Functional MRI (fMRI) Extent of resection Overall survival Progression-free survival 


  1. 1.
    Weller M, Bent MV, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315. Scholar
  2. 2.
    Louis DN, Perry A, Reifenberger G, Deimling AV, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. Scholar
  3. 3.
    Johannesen TB, Langmark F, Lote K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg. 2003;99:854–62.CrossRefGoogle Scholar
  4. 4.
    Van Den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemo-therapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50.CrossRefGoogle Scholar
  5. 5.
    Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.CrossRefGoogle Scholar
  6. 6.
    Stupp R, Brada M, Van Den Bent MJ, et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii93–iii101.CrossRefGoogle Scholar
  7. 7.
    Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefGoogle Scholar
  8. 8.
    Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.CrossRefGoogle Scholar
  9. 9.
    Watts C, Sanai N. Handbook of clinical neurology: Chapter 4 Surgical approaches for the gliomas. 3rd ed. Amsterdam: Elsevier; 2016.Google Scholar
  10. 10.
    Stummer W, Meinel T, Ewelt C, et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108:89–97.CrossRefGoogle Scholar
  11. 11.
    Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Glantz M. Association of the extent of resection with survival in glioblastoma. JAMA Oncol. 2016;2(11):1460. Scholar
  12. 12.
    Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.CrossRefGoogle Scholar
  13. 13.
    Stupp R, Hegi ME, Mason WP, et al. Effects of radio- therapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.CrossRefGoogle Scholar
  14. 14.
    Almenawer SA, Badhiwala JH, Alhazzani W, et al. Biopsy versus partial gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol. 2015;17:868–81.CrossRefGoogle Scholar
  15. 15.
    Bähr O, Steinbach JP, Weller M. Brain tumor imaging. Med Radiol. 2015;3:8–23. Scholar
  16. 16.
    Pernet CR, Gorgolewski KJ, Job D, Rodriguez D, Whittle I, Wardlaw J. A structural and functional magnetic resonance imaging dataset of brain tumour patients. Sci Data. 2016;3:160003. Scholar
  17. 17.
    Petrella JR, Shah LM, Harris KM, et al. Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. Radiology. 2006;240:793–802.CrossRefGoogle Scholar
  18. 18.
    Price SJ, Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006;27:1969–74.PubMedGoogle Scholar
  19. 19.
    Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery. 2007;61:935–48. discussion 948–9CrossRefGoogle Scholar
  20. 20.
    Reinges MH, Nguyen HH, Krings T, et al. Course of brain shift during microsurgical resection of supratentorial cerebral lesions: limits of conventional neuronavigation. Acta Neurochir. 2004;146:369–77. discussion 377CrossRefGoogle Scholar
  21. 21.
    Duffau H, Capelle L. May surgery in eloquent areas induce brain plasticity? Neuroimage. 2000;11((5):S271.CrossRefGoogle Scholar
  22. 22.
    Hou LC, Veeravagu A, Hsu AR, et al. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20:E5.PubMedGoogle Scholar
  23. 23.
    Unsgard G, Solheim O, Lindseth F, et al. Intra-operative imaging with 3D ultrasound in neurosurgery. Acta Neurochir Suppl. 2011;109:181–6.CrossRefGoogle Scholar
  24. 24.
    Solheim O, Selbekk T, Jakola AS, et al. Ultrasound-guided operations in unselected high-grade gliomas – overall results, impact of image quality and patient selection. Acta Neurochir. 2010;152:1873–86.CrossRefGoogle Scholar
  25. 25.
    Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12:997–1003.CrossRefGoogle Scholar
  26. 26.
    Kubben PL, Ter Meulen KJ, Schijns OE, et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12:1062–70.CrossRefGoogle Scholar
  27. 27.
    Vaqas B, et al. OS3.6 Optical biopsies in neurosurgery: raman spectroscopy for the real-time identification of tumours during surgery. Neuro Oncol. 2016;18(suppl_4):iv8.CrossRefGoogle Scholar
  28. 28.
    Zhao S, Wu J, Wang C, et al. Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS One. 2013;8:e63682.CrossRefGoogle Scholar
  29. 29.
    Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008–12.CrossRefGoogle Scholar
  30. 30.
    Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. 2006;148:269–75. discussion 275CrossRefGoogle Scholar
  31. 31.
    Della Puppa A, Lombardi G, Rossetto M, Rustemi O, Berti F, Cecchin D, et al. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. J Neurooncol. 2016;131(2):331–40.CrossRefGoogle Scholar
  32. 32.
    Ryken TC, Kalkanis SN, Buatti JM, et al. The role of cytoreductive surgery in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118:479–88.CrossRefGoogle Scholar
  33. 33.
    Weller M, Platten M, Roth P, et al. Geriatric neuro-oncology: from mythology to biology. Curr Opin Neurol. 2011;24:599–604.CrossRefGoogle Scholar
  34. 34.
    Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol. 2011;13:428–36.CrossRefGoogle Scholar
  35. 35.
    Stummer W, Nestler U, Stockhammer F, et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multi- centric phase II safety study of 5-ALA. J Neurooncol. 2011;103:361–70.CrossRefGoogle Scholar
  36. 36.
    Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, et al. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. J Neurooncol. 2016;128(1):157–62.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of GlasgowGlasgowUK
  2. 2.Division of NeurosurgeryUniversity of CambridgeCambridgeUK
  3. 3.NeurosurgeryUniversity of BirminghamBirminghamUK
  4. 4.Birmingham Brain Cancer ProgramUniversity of BirminghamBirminghamUK
  5. 5.Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
  6. 6.College of Medical and Dental SciencesUniversity of BirminghamBirminghamUK

Personalised recommendations